BridgeBio Oncology <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Poster Presentations on Novel KRAS Inhibitors at 2025 AACR-NCI-EORTC Conference
BridgeBio Oncology Therapeutics Inc. $(BBOT)$ has announced upcoming poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, Massachusetts. The company will present data on BBO-11818, an orally bioavailable, highly potent and selective non-covalent pan-KRAS$(ON)$ and (OFF) inhibitor, which has demonstrated robust anti-tumor activity in KRAS-mutant preclinical models. Additionally, BBOT will present findings on BBO-10203, described as a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, which inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia. The results will be presented during scheduled poster sessions at the conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544680-en) on October 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.